Fusion Antibodies Plc (FAB.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | -376 | -235 | -11 | 6 | -1,127 |
| Accounts receivable | 169 | -158 | -225 | -294 | -67 |
| Other Working Capital | 171 | -126 | -222 | -326 | 143 |
| Other Operating Activity | -124 | -579 | 536 | 577 | 1,397 |
| Operating Cash Flow | $-160 | $-1,098 | $77 | $-37 | $347 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -109 | -1,373 | -445 | -90 | -36 |
| Purchase Sale Intangibles | 0 | -8 | N/A | N/A | N/A |
| Other Investing Activity | 6 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-103 | $-1,381 | $-445 | $-90 | $-36 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -172 | -36 | -25 | N/A | N/A |
| Common Stock Issued | N/A | 0 | 4,599 | 0 | 0 |
| Other Financing Activity | -12 | 9 | -1 | -1 | 0 |
| Financing Cash Flow | $-184 | $-28 | $4,573 | $-1 | $0 |
| Beginning Cash Position | 1,984 | 4,491 | 286 | 414 | 104 |
| End Cash Position | 1,537 | 1,984 | 4,491 | 286 | 414 |
| Net Cash Flow | $-447 | $-2,507 | $4,205 | $-128 | $310 |
| Free Cash Flow | |||||
| Operating Cash Flow | -160 | -1,098 | 77 | -37 | 347 |
| Capital Expenditure | -109 | -1,381 | -445 | -90 | -36 |
| Free Cash Flow | -269 | -2,479 | -367 | -128 | 311 |